Table 4.
Association between EBV-DNA Positivity and Character of Tumors among 120 EBV Seropositive BC Patients
| Tumor characteristics |
No. (%) of cases | No. of EBV-DNA positive cases*/ total No of cases (%) | P value |
|---|---|---|---|
| Tumor size | 0.001 | ||
| Less than 2 cm | 33 (27.5) | 3/33 (9.1) | |
| More than 2 cm | 87 (72.5) | 51/87 (58.6) | |
| Tumor stage | 0.001 | ||
| Stage 1 | 21 (17.5) | 3/21 (14.3) | |
| Stage 2 | 51 (42.5) | 15/51 (29.4) | |
| Stage 3 | 48 (40) | 36/48 (75) | |
| Tumor grade | 0.001 | ||
| Grade 1 | 42 (35) | 6/42 (14.3) | |
| Grade 2 | 36 (30) | 18/36 (50) | |
| Grade 3 | 42 (35) | 30/42 (71.4) | |
| Tumor Histology | 0.001 | ||
| IDC | 102 (85) | 54/102 (52.9)) | |
| ILC | 18 (15) | 0 | |
| Metastasis | 0.001 | ||
| No | 111 (92.5) | 45/111 (40.5) | |
| Yes | 9 (7.5) | 9/9 (100) | |
| ER | 0.6 | ||
| Negative | 57 (47.5) | 27/57 (47.4) | |
| Positive | 63 (52.5) | 27/63 (42.9) | |
| Tumor characteristics |
No. (%) of cases | No. of EBV DNA positive cases*/ total No of cases (%) | |
| PR | |||
| Negative | 66 (55) | 30/66 (45.5) | |
| Positive | 54 (45) | 24/54 (44.4) | |
| HER2 | |||
| Negative | 72(60) | 18/72(25) | |
| Positive | 48(40) | 36/48(75) |
*Total number of EBV DNA-positive in this study was 54 of 120 seropositive positive BC patients; EBV, Epstein-Barr virus; IDC, Infiltrating ductal carcinoma; ILC, Invasive lobular carcinoma; PR, Progesterone receptor; ER, Estrogen receptor; HER2, Human epidermal growth factor receptor-2